Kornimate/medical-research-clean huggingface dataset:
effect of a specific exercise program during pregnancy on diastasis recti abdominis

Conditions: Diastasis Recti Abdominis; Pregnancy Related

Summary: diastasis rectus abdominis is a common condition in pregnant and postpartum women, where the connective tissue between the two muscle bellies of the rectus abdominis muscle is stretched and weakened, causing an increased inter-rectus distance. treatment of this condition aim to reduce the inter-rectus distance, and conservative treatment including therapeutic exercise is the primary treatment of choice. to date, there is no generally accepted protocol of therapeutic exercises for this condition, and the evidence as to which exercise modality is the most effective and feasible in reducing the inter-rectus distance in women presenting with diastasis rectus abdominis is both sparse and weak. as this condition occur during the last two trimesters of pregnancy and as there is a paucity of high-quality studies on a pregnant population, investigators will conduct a randomized controlled trial on the effect of a specific exercise program during pregnancy on diastasis rectus abdominis. 100 pregnant women in gestation week 25 presenting with diastasis rectus abdominis of ≥ 28 mm will be included. participants will be allocated to either an intervention group or a control group by block randomization. the intervention group will participate in a 12-week specific exercise program, consisting of two group sessions and two self-managed sessions weekly. the control group will not participate in any exercise intervention; however, participants will be recommended to follow national guidelines for general exercise during pregnancy. participants will be assessed prior to intervention, post intervention at gestation week 37, and 6 weeks, 6 and 12 months postpartum. the primary outcome measure will be change in the inter-rectus distance in mm, measured by two-dimensional ultrasonography.


Eligibility criteria:
inclusion criteria: * healthy pregnant women * in gestation week 25 * presenting with an inter-rectus distance of 28 mm or more at the level of the umbilicus, and/or 2 cm above and below the umbilicus at rest on initial assessment. participants presenting with a protrusion along the linea alba will also be included, even if they do not meet the inclusion criteria with an inter-rectus distance of 28 mm or more * both primi- and multigravida women will be included, and there will be no limitations on number of fetuses exclusion criteria: * pregnancies where exercise is contraindicated * serious illnesses regarding both mother and fetus * inability to understand scandinavian languages * failure to complete and present an informed consent form * presence of chronic physical or mental illness incompatible with the intervention exclusion criteria during the study period is stillbirth or premature birth before gestation week 37; onset of serious illnesses regarding both mother and foetus; and pregnancies where exercise is contraindicated

Keywords: pregnancy ultrasonography exercise diastasis recti abdominis inter-recti distance
impact of non-commercialism policy in seattle schools

Conditions: Obesity

Summary: this pilot study on the impact of a non-commercialism policy in seattle schools will assess and evaluate obesity-related health outcomes of a real-life policy decision, recently voted on and adopted by the seattle school board. the policy reduces the exposure to advertising and other marketing pressures, including those from commercial food vendors.


Eligibility criteria:
no restrictions

Keywords: obesity in school aged children
smoking cessation and postoperative complications

Conditions: Postoperative Complications; Randomized; Prevention; Smoking Cessation

Summary: the primary aim of this study is to evaluate the effect of preoperative smoking cessation on postoperative complications among patients undergoing surgery. secondary aims are to evaluate effect on wound complications, short and long term effects including abstinence rate, pain, quality of life and effects on the immune system.

tobacco smokers suffers from postoperative complications after surgery more extensively than non-smokers. our primary aim is to study if smoking cessation four weeks prior to elective surgery decreases the number of postoperative complications. secondary aims is to analyse if smoking cessation four weeks prior to elective surgery decreases wound complications, analyse the effect on abstinence rate, effect on postoperative pain, quality of life and if smoking cessation normalises; the immunological response to surgery. the study is randomised, prospective, multicenter-based trial. daily smokers are randomised to 1. control group (standard care) or 2. smoking cessation. patients randomised to smoking cessation will undergo professional motivational counselling and will receive free nicotine substitution. the study will include elective cases that are scheduled for surgery. cessation starts 3-5 weeks prior to surgery. all patients are prospectively followed up for four weeks concerning post-operative complications and for one year concerning other outcomes. outcome (complications) is registered by a blind observer. analyses will be performed by intention to treat. the intervention group is compared with the control group and an adjustment for possible confounders will be done. there will also be an analysis in the subgroups depending on which surgical procedure was performed.secondary analyses will be by protocol

Eligibility criteria:
inclusion criteria: * active, daily tobacco smokers (\> 2 cigarettes daily for at least one year prior to inclusion), 18-79 years old at the time of randomisation. * proficiency in the swedish language. * oral and written consent. * scheduled for primary inguinal hernia repair or other umbilical hernia repair or laparoscopic cholecystectomy * scheduled for hip- or knee replacement exclusion criteria: * - active drug abuse or severe mental illness prohibiting compliance with the study protocol. * pregnancy. * residence outside the county of stockholm.
study of gsk3511294 in healthy chinese participants

Conditions: Asthma

Summary: this single dose pharmacokinetic (pk) study aims to investigate the pk, safety, tolerability and immunogenicity of two dose levels of gsk3511294 administered subcutaneously in chinese healthy participants


Eligibility criteria:
inclusion criteria: * participant between 18 to 45 years of age. * participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, electrocardiograms and vital signs. * body weight greater than or equal to (\>=)50.0 kilograms (kg) for males, \>=45.0 kg for females, and body mass index (bmi) within the range (19.0-26.0) kg/meter square (m\^2) (inclusive). * contraceptive use by men and/or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * capable of giving signed informed consent. exclusion criteria: * participant is pregnant, breastfeeding, or a woman of childbearing potential * history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs * participants with allergy/intolerance to a monoclonal antibody or biologic or participants with a previous history of clinically significant multiple or severe allergic reactions/intolerance * current evidence or recent history of an infective illness * a positive pre-study drug/alcohol screen or a history (or suspected history) of alcohol misuse or substance abuse * clinically significant abnormalities * participants with coronavirus disease-2019 (covid-19) * with prior/concurrent clinical study experience.

Keywords: single dose study immunogenicity gsk3511294 chinese healthy participants
evaluation of the use of ozone gel versus hyaluronic acid gel on palatal wound healing .

Conditions: Palate; Wound

Summary: to compare the effect of ozone gel versus hyaluronic acid gel 0.2% applied to palatal donor site in post-operative pain reduction after free gingival graft harvesting.

to compare the effect of ozone gel versus hyaluronic acid gel 0.2% applied to palatal donor site in post-operative pain reduction , color match , wound size closure after free gingival graft harvesting.

Eligibility criteria:
inclusion criteria: * patients with mucogingival defects scheduled for free gingival graft * systemically healthy exclusion criteria: * smokers * occlusal trauma at site of graft * pregnancy and lactation * patients allergic to the used agents * severe gagging reflex
pharmacokinetics of miltefosine in children and adults

Conditions: Cutaneous Leishmaniasis

Summary: the purpose of this study is to determine the pharmacokinetics of miltefosine in children and adults with cutaneous leishmaniasis in plasma and intracellularly, and its relation with the parasitologic response. the results will provide pharmacologic bases to optimize the use of miltefosine for the treatment of cutaneous leishmaniasis, and will provide the knowledge base to assess the impact of pharmacokinetic behavior in children and adults on the emergence of drug resistance.

an open-label phase iv clinical trial of miltefosine, designed to evaluate intracellular and plasma drug pharmacokinetics in children and adults using a population pharmacokinetics design. two study groups have been defined: 1) children 2-12 years of age (n=30) and 2) adults 18-60 years of age (n=30) with confirmed parasitological diagnosis of cutaneous leishmaniasis. the participants will receive supervised standard treatment with miltefosine: 1.8 - 2.5 mg/kg of weight for 28 days. miltefosine concentration will be determined in plasma and peripheral blood mononuclear cell (pbmcs), from 3 or 10ml peripheral blood samples in children and adults respectively. sampling will be conducted pre-dosing at days 0,1,15 and 29 during treatment, and at months 1, 2, 3 and 6 post-treatment. a population pharmacokinetics analysis will be performed using a non-linear model of mixed effects with the software nonlinear mixed-effects model (nonmem), r and piranha. parasite burden will be determined by 7slrna quantitative polymerase chain reaction (qpcr) of leishmania from swab samples of lesions and extralesional tissues before and at the end of treatment. the relationship between pharmacokinetics and parasite persistence/burden will be determined by correlation analysis and pharmacodynamic modeling.

Eligibility criteria:
inclusion criteria: * age: 2-12 years of age, or 18-60 years of age * weight greater than 10 kg * parasitologic confirmation of cutaneous leishmaniasis * normal hepatic and kidney function exclusion criteria: * pregnant or lactating women, and women who are planning to conceive during the study or that reject the use of birth control methods. * use of drugs with antileishmanial potential during the previous 6 months, including pentavalent antimonials, amphotericin b, miltefosine, and pentamidine * mucocutaneous or visceral leishmaniasis * for female children, menses or other evidence of reproductive maturity

Keywords: miltefosine pharmacokinetics cutaneous leishmaniasis
evaluation of the ps100b for the diagnostic of stroke with patients out of delay for thrombolysis or thrombectomy

Conditions: Stroke

Summary: numerous patients are addressed to the emergency department for unspecific symptoms which can evoke a stroke, such as vertigo, isolated motor deficit, behavior disorder. for these patients, when they arrive out of time for specific treatments such as thrombolysis and thrombectomy, the cerebral imagery is not an emergency, but necessary to confirm or invalidate the diagnostic of stroke. if a biomarker could exclude the diagnostic of stroke, we could avoid an imagery for these patients. ps100b is a biomarker whose blood level increases in case of stroke. it has already proven a prognostic value. until now, it hasn't proven a diagnostic value because it take a few hours to increase in the blood. it could have in prognostic value for patients who have the symptoms for more than 24 hours. stroke is a diagnostic, prospective, monocentric study, conducted at university hospital center of poitiers (france). the aim is to determine the value of ps100b to exclude the diagnostic of a stroke in case of evocative symptoms, for patients who are out of delay for a thrombolysis or a thrombectomy. patients eligible are the ones who present to the emergency department with symptoms evocative of stroke for more than 24 hours and less than 4 days. patients included have a sample of blood withdrawn, in order to measure ps100b blood level. the diagnostic of stroke is than confirmed or excluded by an adjudication comity, who are unaware of the result of ps100b blood level. the diagnostic value of ps100b is determined with the help of a roc curve.


Eligibility criteria:
inclusion criteria: * patients presenting at the emergency department of the university hospital center of poitiers for the following symptoms, which last since more then 24 hours et less then 4 days : * sensitive or motor deficit of one or several limbs * facial paralysis * impairment of speech * dysarthria * vertigo * impairment of vision * oculomotor disorder * diplopia * free patient, without guardianship or curatorship, or subordination * patient not objecting to research exclusion criteria: * head trauma that occured less then 15 days ago * known cerebral mass or melanoma * refusal to participate in research * patient benefiting from enhanced protection, namely: minors, persons deprived of their liberty by a judicial or administrative decision, adults under legal protection * pregnant and/or breastfeeding women

Keywords: ps100b stroke out of delay diagnostic
registry for longitudinal mortality and therapy in patients with heart failure

Conditions: Heart Failure

Summary: the purpose of this registry is to compile a large clinical database on the medical management of patients hospitalized with acute heart failure, using information collected from hospitals across china.

registry for longitudinal mortality and therapy in patients with heart failure is a large, multicenter, prospective, open-label registry of the management of patients treated in the hospital for acute heart failure in china. the objective of this study is to investigate the clinical features and prognosis of patients with heart failure, and discover the characteristics of high-risk heart failure patients, and elucidate critical factors which predict the development and outcomes of symptomatic heart failure patients. 1. to elucidate the clinical characteristics and prognostic risks of patients with heart failure. 2. to study the characteristics of high-risk heart failure patients and predict the key factors for the development of symptomatic heart failure patients. 3. to elucidate the compliance of patients with heart failure and the incidence of adverse drug effects. 4. to investigate the effect of self-management on outcomes in patients with heart failure. 5. to elucidate critical factors associated with the development and outcomes of heart failure. 6. to investigate hospitalization expenses for heart failure.

Eligibility criteria:
inclusion criteria: - 1. 18 years and older. 2. meet the diagnostic criteria of china 2018 or jacc/aha 2017 or esc 2016 heart failure guidelines. 3. agree to be tested and sign an informed consent certificate. exclusion criteria: * 1. age\<18 years old. 2. patients who refused to participate. 3. patients may have a life expectancy of less than 1 years due to non- heart failure clinical conditions.

Keywords: heart failure,prognostic, registry
investigation of a combination treatment of escitalopram and rtms

Conditions: Major Depressive Disorder

Summary: we intend to test in a randomized, rater blinded, placebo controlled, prospective study the primary hypothesis that an escitalopram-rtms-combination treatment is more efficacious in the treatment of refractory major depression assessed with the hamilton depression rating scale

we intend to test in a randomized, rater blinded, placebo controlled, prospective study the primary hypothesis that an escitalopram-rtms-combination treatment is more efficacious in the treatment of refractory major depression assessed with the hamilton depression rating scale compared to placebo. a second hypothesis is that the treatment of mde with escitalopram (that means in the "placebo group") alone lead to typical changes like * an increase in neurotrophic factors concentration (measured by blood concentrations of nerve growth factor (ngf) and brain derived nerve growth factor (bdnf), * an increase in hippocampal metabolites (measured with magnetic resonance spectroscopy (mrs * an increase in motor cortical inhibitory activity (measured with motor evoked potentials (mep * an increase in serotonergic activity (measured with eeg parameters, moreover, it is hypothesized that similar but pronounced changes occur in the group treated with the combination treatment.

Eligibility criteria:
inclusion criteria: * major depressive episode (according to dsm iv standards) * hamd \> 20 * patient has an iq \> 70 based on the investigator´s judgement * patient is male or nonpregnant female adequately protected from conception * patient is able to comply with all testing and follow-up visit requirements defined by the study protocol * patient has voluntarily signed an informed consent in accordance with institutional policies exclusion criteria: * patient has a history of schizophrenia, schizoaffective disorder or delusional disorder * patient currently has a secondary diagnosis of, or signs of, delirium, dementia, amnestic or other cognitive disorder per dsm iv * patient is suicidal * patient has had an alcohol or substance dependence within the previous 12 month * patient is currently enrolled in another investigational study * patient has a history of, or evidence of, significant central nervous disease (especially seizures) * patient has previously been treated with escitalopram * contraindication against escitalopram or rtms

Keywords: major depressive disorder repetitive transcranial magnetic stimulation
pain and stress detection and relief in people with dementia

Conditions: Dementia; Chronic Pain; Perceived Stress

Summary: the objective of this study is to investigate the feasibility and efficacy of using the portable eeg headband and the headband-guided meditation practices for pain and stress relief in people with dementia in hong kong. additionally, it explores the potential use of the headband as a biomarker for pain and stress in this target group.

this project is a phase ii clinical trial to access the feasibility and efficacy of incorporating portable eeg headband-guided meditation for alleviating pain and stress among people with early and moderate dementia in hong kong. sixty dementia people will be recruited. participants in the intervention group will wear the eeg headband and engage in 10-minute guided meditation sessions, while the control group will wear the eeg headband and undergo a 10-minute resting session. efficacy will be evaluated using the wong-baker faces pain rating scale, perceived stress scale, and eeg signals associated with pain and stress. immediate post-assessment focus group interviews will be conducted to explore caregiver's experiences with the use of portable eeg headbands in this study.

Eligibility criteria:
inclusion criteria: * people with mild to moderate severe dementia; * have chronic pain or have experienced stress for at least six months; * be able to communicate and express pain; * have no prior experience with any type of meditation training; * volunteer to participate in the study and provide written informed consent exclusion criteria: * person with other acute or terminal illnesses that may not be able to stay in a home living environment frequently; * with severe visual or hearing problems that would hinder communication; * with infectious diseases that could be transmitted by using the headband.

Keywords: dementia pain stress
repetitive transcranial stimulation (r-tms) treatment for patients with parkinson's disease

Conditions: Parkinson's Disease

Summary: the purpose of this study is to test the effects of deep rtms using the novel h-coil on the motor, affective and cognitive deficits in patients with parkinson's disease (pd) and to establish its safety in this population.

study rational:we anticipate that reaching deeper brain layers and larger volume of activation with the novel h-coil may induce significantly better therapeutic effects in patients with pd and will pave the way for establishing a novel and effective treatment for this disorder. design:a prospective, double blind sham-controled study. no. of centers:1 one: tel-hashomer medical center, affiliated to sackler school of medicine, tel -aviv university, israel. study population:forty patients with idiopathic pd, hoehn and yahr stages ii to iv, on stable antiparkinsonian therapy, with partial response. study duration:two years

Eligibility criteria:
inclusion criteria: * pd patients aged 40 years or older, diagnosed as idiopathic pd according to the uk brain bank criteria, with hoehn \& yahr stages ii - iv while "off". participants on antidepressants should be at least 2 months on stable therapy. exclusion criteria: * patients who have concomitant epilepsy, a history of seizure or heat convulsion or history of epilepsy in first degree relative. * patients on neuroleptics. * patients with dementia or any unstable medical disorder. * history or current hypertension. * history of head injury or neurosurgical interventions. * history of any metal in the head (outside the mouth). * known history of any metallic particles in the eye, implanted cardiac pacemaker or any intracardiac lines, implanted neurostimulators, surgical clips or any medical pumps. * history of migraine or frequent or severe headaches. * history of hearing loss. * the presence of cochlear implants * history of drug abuse or alcoholism. * pregnancy or not using a reliable method of birth control. * participation in current clinical study or clinical study within 30 days prior to this study.

Keywords: repetitive transcranial stimulation parkinson's disease
a clinical study comparing the comfort of three commercially available contact lenses

Conditions: Contact Lens Complication

Summary: the purpose of this study is to compare the comfort of three commercially available contact lenses.


Eligibility criteria:
inclusion criteria: * be at least 18 years old * have provided written informed consent * have discomfort when wearing contact lenses exclusion criteria: * have an active ocular infection or significant slit lamp findings * participated in any other studies in the past 30 days